Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RBOT Stock Forecast 2025-2026
$8.74
Current Price
$51.14M
Market Cap
Buy 1
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to RBOT Price Targets
+48.8%
To High Target of $13.00
+23.0%
To Median Target of $10.75
-2.7%
To Low Target of $8.50
RBOT Price Momentum
+4.2%
1 Week Change
+64.3%
1 Month Change
+0.5%
1 Year Change
-33.6%
Year-to-Date Change
-54.0%
From 52W High of $19.00
+104.6%
From 52W Low of $4.27
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching D8 Holdings (RBOT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on RBOT and similar high-potential opportunities.
Latest RBOT Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, RBOT has a neutral consensus with a median price target of $10.75 (ranging from $8.50 to $13.00). Currently trading at $8.74, the median forecast implies a 23.0% upside. This outlook is supported by 1 Buy, 2 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Adam Maeder at Piper Sandler, suggesting a 2.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RBOT Analyst Ratings
1
Buy
2
Hold
0
Sell
RBOT Price Target Range
Low
$8.50
Average
$10.75
High
$13.00
Current: $8.74
Latest RBOT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RBOT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 18, 2025 | Piper Sandler | Adam Maeder | Neutral | Maintains | $8.50 |
| Nov 13, 2024 | Piper Sandler | Adam Maeder | Neutral | Maintains | $10.50 |
| Aug 13, 2024 | Piper Sandler | Adam Maeder | Neutral | Maintains | $12.00 |
| Jul 15, 2024 | Morgan Stanley | Patrick Wood | Equal-Weight | Maintains | $10.00 |
| Mar 5, 2024 | Piper Sandler | Adam Maeder | Neutral | Maintains | $1.00 |
| Dec 4, 2023 | Morgan Stanley | Patrick Wood | Equal-Weight | Initiates | $0.60 |
| Nov 14, 2023 | Canaccord Genuity | Caitlin Cronin | Hold | Downgrade | $0.40 |
| Nov 14, 2023 | BTIG | Ryan Zimmerman | Neutral | Downgrade | $0.00 |
| May 31, 2023 | Canaccord Genuity | Kyle Rose | Buy | Maintains | $9.00 |
| Jul 18, 2022 | BTIG | Ryan Zimmerman | Buy | Maintains | $7.00 |
| May 10, 2022 | Piper Sandler | Adam Maeder | Neutral | Maintains | $5.00 |
| Mar 4, 2022 | Canaccord Genuity | Buy | Maintains | $0.00 | |
| Mar 4, 2022 | Piper Sandler | Adam Maeder | Neutral | Downgrade | $7.00 |
| Jan 7, 2022 | Credit Suisse | Outperform | Initiates | $0.00 | |
| Dec 7, 2021 | Cowen & Co. | Outperform | Initiates | $0.00 | |
| Nov 5, 2021 | Canaccord Genuity | Buy | Initiates | $0.00 | |
| Oct 18, 2021 | BTIG | Buy | Initiates | $0.00 | |
| Oct 7, 2021 | Piper Sandler | Overweight | Initiates | $0.00 |
Vicarious Surgical Inc. (RBOT) Competitors
The following stocks are similar to D8 Holdings based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Vicarious Surgical Inc. (RBOT) Financial Data
Vicarious Surgical Inc. has a market capitalization of $51.14M with a P/E ratio of 49.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -87.4%.
Valuation Metrics
Market Cap
$51.14M
Enterprise Value
$17.11M
P/E Ratio
49.0x
PEG Ratio
-1.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+94.8%
Current Ratio
6.7x
Debt/Equity
29.5x
ROE
-87.4%
ROA
-44.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Vicarious Surgical Inc. (RBOT) Business Model
About Vicarious Surgical Inc.
What They Do
Develops advanced surgical robotics with VR integration.
Business Model
The company designs and develops proprietary surgical robots that enhance surgical procedures through advanced technology. By focusing on minimally invasive surgeries and improving surgical precision and control, it generates revenue from the sale and integration of its robotic systems into hospitals and clinics.
Additional Information
Vicarious Surgical's innovative approach aims to improve patient outcomes, reduce recovery times, and increase the accessibility of complex surgeries. By being at the forefront of medical technology, the company plays a crucial role in the evolution of healthcare practices worldwide.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
123
CEO
Mr. Adam David Sachs
Country
United States
IPO Year
2017
Website
www.vicarioussurgical.comVicarious Surgical Inc. (RBOT) Latest News & Analysis
Latest News
Quick Summary
Vicarious Surgical Inc. (NYSE: RBOT) will report Q1 2025 financial results on May 12, 2025, after market close, followed by a conference call at 4:30 PM ET.
Why It Matters
The upcoming financial results and conference call could reveal key insights into Vicarious Surgical's performance and growth potential, influencing stock valuation and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Vicarious Surgical Inc. (NYSE: RBOT) has received a notice from the NYSE stating it is not in compliance with listing standards as of April 10, 2025.
Why It Matters
Vicarious Surgical's non-compliance with NYSE listing standards could lead to delisting, impacting stock value and investor confidence, signaling potential financial instability.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Vicarious Surgical Inc. (NYSE: RBOT) announced that President Randy Clark will transition to Board Member on April 25, 2025, pending conflict checks. He oversaw key business functions.
Why It Matters
Randy Clark's transition to Board Member may signal strategic shifts in leadership, impacting Vicarious Surgical's direction and investor confidence in its robotics innovations.
Source: Business Wire
Market Sentiment:
Neutral
What Makes D8 (RBOT) a New Buy Stock
1 month ago
Quick Summary
D8 (RBOT) has been upgraded to a Zacks Rank #2 (Buy) due to increasing optimism about its earnings prospects, indicating potential for higher stock performance.
Why It Matters
D8's upgrade to Zacks Rank #2 signals strong earnings potential, likely boosting investor confidence and attracting more buyers, which can drive up the stock price.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Vicarious Surgical Inc. (NYSE:RBOT) will hold its Q4 2024 earnings call on March 17, 2025, at 4:30 PM ET, featuring key executives and analysts from BTIG, Piper Sandler, and Cowen.
Why It Matters
The scheduled earnings call for Vicarious Surgical provides insights into financial performance and strategic direction, influencing investor sentiment and stock price movements.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Vicarious Surgical Inc. (NYSE: RBOT) reported its financial results for Q4 and full year 2024. A conference call is scheduled for March 17, 2025, at 4:30 p.m. ET to discuss the results.
Why It Matters
Financial results indicate company performance and growth potential. The conference call provides insights into future strategies, affecting stock valuations and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About RBOT Stock
What is Vicarious Surgical Inc.'s (RBOT) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Vicarious Surgical Inc. (RBOT) has a median price target of $10.75. The highest price target is $13.00 and the lowest is $8.50.
Is RBOT stock a good investment in 2025?
According to current analyst ratings, RBOT has 1 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.74. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RBOT stock?
Wall Street analysts predict RBOT stock could reach $10.75 in the next 12 months. This represents a 23.0% increase from the current price of $8.74. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vicarious Surgical Inc.'s business model?
The company designs and develops proprietary surgical robots that enhance surgical procedures through advanced technology. By focusing on minimally invasive surgeries and improving surgical precision and control, it generates revenue from the sale and integration of its robotic systems into hospitals and clinics.
What is the highest forecasted price for RBOT Vicarious Surgical Inc.?
The highest price target for RBOT is $13.00 from at , which represents a 48.8% increase from the current price of $8.74.
What is the lowest forecasted price for RBOT Vicarious Surgical Inc.?
The lowest price target for RBOT is $8.50 from Adam Maeder at Piper Sandler, which represents a -2.7% decrease from the current price of $8.74.
What is the overall RBOT consensus from analysts for Vicarious Surgical Inc.?
The overall analyst consensus for RBOT is neutral. Out of 6 Wall Street analysts, 1 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $10.75.
How accurate are RBOT stock price projections?
Stock price projections, including those for Vicarious Surgical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 5:03 PM UTC